Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD

Affiliations

• ¹ Department of Medicine, Oregon Health and Science University, Knight Cancer Institute, Portland, OR, USA. meyersg@ohsu.edu.
• ² BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
• ³ Medical College of Wisconsin, Milwaukee, WI, USA.
• ⁴ Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical, Duarte, CA, USA.
• ⁵ Division of Hematology, The Ohio State University Comprehensive Cancer Center-James, Columbus, OH, USA.
• ⁶ The Emmes Company, Rockville, MD, USA.
• ⁷ MSK Kids Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ⁸ Xenikos BV, Nijmegen, The Netherlands.
• ⁹ National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
• ¹⁰ Blood and Marrow Transplantation & Cellular Therapy Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
• ¹¹ H. Lee Moffitt Cancer Center, Tampa, FL, USA.
• ¹² Division of Oncology, BMT and Leukemia Section, Washington University School of Medicine, St. Louis, MO, USA.
• ¹³ Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
• ¹⁴ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.